Tecartus™ (brexucabtagene autoleucel) – New orphan drug approval
July 24, 2020, Gilead announced the FDA approval of Tecartus (brexucabtagene autoleucel), for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL).
Download PDF
